The current trajectory of the Preclinical CRO Market Growth is inextricably linked to the seismic shift in the pharmaceutical pipeline away from traditional small molecules and toward complex biological entities. The development of large-molecule biologics, including monoclonal antibodies, cell therapies, and cutting-edge gene therapies, necessitates specialized and often proprietary testing...